Your browser doesn't support javascript.
loading
Allogeneic hematopoietic cell transplantation with non-myeloablative conditioning for patients with hematologic malignancies: Improved outcomes over two decades.
Cooper, Jason P; Storer, Barry E; Granot, Noa; Gyurkocza, Boglark; Sorror, Mohamed L; Chauncey, Thomas R; Shizuru, Judith; Franke, Georg-Nikolaus; Maris, Michael B; Boyer, Michael; Bruno, Benedetto; Sahebi, Firoozeh; Langston, Amelia A; Hari, Parameswaran; Agura, Edward D; Lykke Petersen, Søren; Maziarz, Richard T; Bethge, Wolfgang; Asch, Julie; Gutman, Jonathan A; Olesen, Gitte; Yeager, Andrew M; Hübel, Kai; Hogan, William J; Maloney, David G; Mielcarek, Marco; Martin, Paul J; Flowers, Mary E D; Georges, George E; Woolfrey, Ann E; Deeg, Joachim H; Scott, Bart L; McDonald, George B; Storb, Rainer; Sandmaier, Brenda M.
Afiliação
  • Cooper JP; Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.
  • Storer BE; Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.
  • Granot N; Fred Hutchinson Cancer Research Center, Seattle, WA, USA.
  • Gyurkocza B; Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.
  • Sorror ML; Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.
  • Chauncey TR; Fred Hucthinson Cancer Research Center, Univ of Washington, VA Puget Sound Health Care, Seattle, USA.
  • Shizuru J; Stanford University, Palo Alto, CA, USA.
  • Franke GN; University of Leipzig, Leipzig, Germany.
  • Maris MB; Colorado Blood Cancer Institute at HealthONE Presbyterian/St. Luke Medical Center, Denver, USA.
  • Boyer M; University of Utah, Salt Lake City, UT, USA.
  • Bruno B; Azienda Ospedaliera S Giovanni Battista, University of Turin, Turin, Italy.
  • Sahebi F; City of Hope/Kaiser Permanente Medical Group, Duarte, CA, USA.
  • Langston AA; Winship Cancer Institute at Emory University, Atlanta, GA, USA.
  • Hari P; Medical College of Wisconsin, Milwaukee, WI, USA.
  • Agura ED; Baylor University, Dallas, TX, USA.
  • Lykke Petersen S; University of Copenhagen Rigshospitalet, Copenhagen, Denmark.
  • Maziarz RT; Oregon Health and Science University, Portland, OR, USA.
  • Bethge W; Medical Center University of Tübingen, Tübingen, Germany.
  • Asch J; LDS Hospital, Salt Lake City, UT, USA.
  • Gutman JA; University of Colorado, Denver, CO, USA.
  • Olesen G; Aarhus University, Aarhus, Denmark.
  • Yeager AM; University of Arizona Cancer Center, Tucson, AZ, USA.
  • Hübel K; University Hospital of Cologne, Cologne, Germany.
  • Hogan WJ; Mayo Clinic, Rochester, MN, USA.
  • Maloney DG; Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.
  • Mielcarek M; Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.
  • Martin PJ; Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.
  • Flowers MED; Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.
  • Georges GE; Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.
  • Woolfrey AE; Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.
  • Deeg JH; Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.
  • Scott BL; Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.
  • McDonald GB; Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.
  • Storb R; Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.
  • Sandmaier BM; Fred Hutchinson Cancer Research Center and the University of Washington, Seattle, WA, USA.
Haematologica ; 106(6): 1599-1607, 2021 06 01.
Article em En | MEDLINE | ID: mdl-32499241
ABSTRACT
We have used a non-myeloablative conditioning regimen for allogeneic hematopoietic cell transplantation for the past twenty years. During that period, changes in clinical practice have been aimed at reducing morbidity and mortality from infections, organ toxicity, and graft-versus-host disease. We hypothesized that improvements in clinical practice led to better transplantation outcomes over time. From 1997-2017, 1,720 patients with hematologic malignancies received low-dose total body irradiation +/- fludarabine or clofarabine before transplantation from HLA-matched sibling or unrelated donors, followed by mycophenolate mofetil and a calcineurin inhibitor ± sirolimus. We compared outcomes in three cohorts by year of transplantation 1997 +/- 2003 (n=562), 2004 +/- 2009 (n=594), and 2010 +/- 2017 (n=564). The proportion of patients ≥60 years old increased from 27% in 1997 +/- 2003 to 56% in 2010-2017, and with scores from the Hematopoietic Cell Transplantation Comborbidity Index of ≥3 increased from 25% in 1997 +/- 2003 to 45% in 2010 +/- 2017. Use of unrelated donors increased from 34% in 1997 +/- 2003 to 65% in 2010-2017. When outcomes from 2004 +/- 2009 and 2010-2017 were compared to 1997 +/- 2003, improvements were noted in overall survival (P=.0001 for 2004-2009 and P <.0001 for 2010-2017), profression-free survival (P=.002 for 2004-2009 and P <.0001 for 2010 +/- 2017), non-relapse mortality (P<.0001 for 2004 +/- 2009 and P <.0001 for 2010 +/- 2017), and in rates of grades 2 +/- 4 acute and chronic graft-vs.-host disease. For patients with hematologic malignancies who underwent transplantation with non-myeloablative conditioning, outcomes have improved during the past two decades. Trials reported are registered under ClinicalTrials.gov identifiers NCT00003145, NCT00003196, NCT00003954, NCT00005799, NCT00005801, NCT00005803, NCT00006251, NCT00014235, NCT00027820, NCT00031655, NCT00036738, NCT00045435, NCT00052546, NCT00060424, NCT00075478, NCT00078858, NCT00089011, NCT00104858, NCT00105001, NCT00110058, NCT00397813, NCT00793572, NCT01231412, NCT01252667, NCT01527045.
Assuntos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Neoplasias Hematológicas / Doença Enxerto-Hospedeiro Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Humans / Middle aged Idioma: En Revista: Haematologica Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Transplante de Células-Tronco Hematopoéticas / Neoplasias Hematológicas / Doença Enxerto-Hospedeiro Tipo de estudo: Etiology_studies / Prognostic_studies Limite: Humans / Middle aged Idioma: En Revista: Haematologica Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Estados Unidos